Drug–Lipid Conjugates for Enhanced Oral Drug Delivery

被引:0
|
作者
Tushar Date
Kaushani Paul
Navneet Singh
Sanyog Jain
机构
[1] National Institute of Pharmaceutical Education and Research (NIPER),Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics
来源
关键词
lipid–drug conjugate; permeability; oral drug delivery; bioavailability;
D O I
暂无
中图分类号
学科分类号
摘要
Oral drug delivery route is one of the most convenient and extensively utilised routes for drug administration. But there exists class of drugs which exhibit poor bioavailability on oral drug administration. Designing of drug–lipid conjugates (DLCs) is one of the rationale strategy utilised in overcoming this challenge. This review extensively covers the various dimensions of drug modification using lipids to attain improved oral drug delivery. DLCs help in improving oral delivery by providing benefits like improved permeability, stability in gastric environment, higher drug loading in carriers, formation of self-assembled nanostructures, etc. The clinical effectiveness of DLCs is highlighted from available marketed drug products along with many DLCs in phase of clinical trials. Conclusively, this drug modification strategy can potentially help in augmenting oral drug delivery in future.
引用
收藏
相关论文
共 50 条
  • [41] Lipid formulation as a drug carrier for drug delivery
    Tomii, Y
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (06) : 467 - 474
  • [42] Antibody-drug conjugates: targeted drug delivery for cancer
    Alley, Stephen C.
    Okeley, Nicole M.
    Senter, Peter D.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) : 529 - 537
  • [43] Advances in the development of aptamer drug conjugates for targeted drug delivery
    Chen, Ke
    Liu, Bo
    Yu, Bo
    Zhong, Wen
    Lu, Yi
    Zhang, Jiani
    Liao, Jie
    Liu, Jun
    Pu, Ying
    Qiu, Liping
    Zhang, Liqin
    Liu, Huixia
    Tan, Weihong
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2017, 9 (03)
  • [44] Polysaccharide-drug conjugates as controlled drug delivery systems
    Nichifor, M.
    Mocanu, G.
    POLYSACCHARIDES FOR DRUG DELIVERY AND PHARMACEUTICAL APPLICATIONS, 2006, 934 : 289 - 303
  • [45] Progress in Lipid and Inorganic Nanocarriers for Enhanced Skin Drug Delivery
    Albakr, Lamyaa
    Du, Hongyuan
    Zhang, Xiyuan
    Kathuria, Himanshu
    Anwar-Fadzil, Ahmed Fahmi
    Wheate, Nial J.
    Kang, Lifeng
    ADVANCED NANOBIOMED RESEARCH, 2024, 4 (06):
  • [46] Folic Acid Functionalized Nanoparticles for Enhanced Oral Drug Delivery
    Roger, Emilie
    Kalscheuer, Stephen
    Kirtane, Ameya
    Guru, Bharath Raja
    Grill, Alex E.
    Whittum-Hudson, Judith
    Panyam, Jayanth
    MOLECULAR PHARMACEUTICS, 2012, 9 (07) : 2103 - 2110
  • [47] Development and characterization of anionic liposaccharides for enhanced oral drug delivery
    Abdelrahim, Adel S.
    Simerska, Pavla
    Toth, Istvan
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 430 (1-2) : 120 - 128
  • [48] Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system
    Ke, Weilun
    Zhao, Yansong
    Huang, Rongqin
    Jiang, Chen
    Pei, Yuanying
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (06) : 2208 - 2216
  • [49] Maytansinoids in cancer therapy: advancements in antibody-drug conjugates and nanotechnology-enhanced drug delivery systems
    Perra, Matteo
    Castangia, Ines
    Aroffu, Matteo
    Fulgheri, Federica
    Abi-Rached, Rita
    Manca, Maria Letizia
    Cortes, Hernan
    Del Prado-Audelo, Maria Luisa
    Nomura-Contreras, Carla
    Romero-Montero, Alejandra
    Busselberg, Dietrich
    Leyva-Gomez, Gerardo
    Sharifi-Rad, Javad
    Calina, Daniela
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [50] Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors
    Okur, Neslihan Ustundag
    Siafaka, Panoraia, I
    Gokce, Evren Homan
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2021, 22 (07) : 892 - 905